Cancer, Rare Disease Drugs Among New China Approvals
Takeda, Bayer Gain Along with Dompe, Henlius
Executive Summary
Rare disease and cancer treatments are front and center in the latest batch of China new drug approvals, while biosimilars are expected to move into the spotlight.
You may also be interested in...
Chinese Firms At JPM Not About China, It’s Time To Go Global
From BeiGene to Innovent to Wuxi Biologics, executives at Chinese pharma firms are now discussing collaborations to go beyond China to become biopharma operations with a truly global presence.
Vaccine, Antibody Race On As Omicron Spreads In China
An oral vaccine candidate from Hong Kong and domestically-developed antivirals and antibodies join the ongoing development fight as Tianjin city reports new Omicron outbreak.
Xian Under Lockdown, mRNA Vaccines Remain Elusive In China
A relatively large outbreak in another major Chinese city after original epicenter Wuhan heightens the urgency for a more effective mRNA vaccine.